Abstract
Objectives: To identify factors associated with long-term opioid therapy (L-TOT) discontinuation in people with chronic non-cancer pain (CNCP). Design and setting: Population-based retrospective cohort study using UK Clinical Practice Research Datalink Aurum data between 01/01/2000-31/12/2020. Population: The study cohort comprised adults (>=18 years) with CNCP who were using L-TOT, defined as >=3 opioid prescriptions within 90 days, or a >=90 days of supply within the first year, excluding the first 30 days. Main outcome measures: Discontinuation was defined as opioid-free for >=180 days following an episode of L-TOT. Mixed-effects logistic models with a random intercept for general practice were used to identify sociodemographic, comorbidities, lifestyle and pharmacological factors associated with L-TOT discontinuation. Results: Among 573,639 L-TOT users, 5.2% (n=29,589) discontinued (mean age 56.45+/-18.41, female 60.04%) within the first year. Factors significantly associated with a higher likelihood of L-TOT discontinuation included being Asian (adjusted odds ratio: 1.31, 95% confidence interval: 1.23 to 1.39) or Black (1.21, 1.13 to 1.31), a non-smoker (1.09, 1.05 to 1.12) or a former smoker (1.05, 1.02 to 1.09), living in the least deprived area (1.09, 1.04 to 1.14), using weak and short-acting opioids (1.50, 1.39 to 1.61), coexisting osteoarthritis (1.06, 1.02 to 1.11) or anxiety (1.04, 1.01 to 1.07), and concurrently using non-steroidal anti-inflammatory drugs (1.06, 1.03 to 1.09) or benzodiazepines (1.08, 1.05 to 1.11). Those younger (0.990, 0.988 to 0.992), with lower daily dose (0.981, 0.980 to 0.982), substance use disorder (0.77, 0.72 to 0.83), and taking gabapentinoids (0.83, 0.69 to 1.00) or antidepressants (0.89, 0.87 to 0.92) were less likely to discontinue L-TOT. Conclusions: This study identified key characteristics of people with CNCP who are more likely to discontinue L-TOT in UK primary care. Such information can help to guide the development of targeted, personalised interventions to support safe and effective opioid discontinuation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The data access costs were fully supported by the NIHR (National Institute for Health and Care Research) Greater Manchester Patient Safety Research Collaboration. The funders had no role in study design, data collection, analysis, interpretation, writing, or the decision to submit the article. The views expressed are those of the authors and do not necessarily reflect those of the NIHR.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Clinical Practice Research Datalink Independent Scientific Advisory Committee gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos